On 21 April 2023, the Therapeutic Goods Administration (TGA) approved Moderna Australia’s application to transition its original/ancestral strain COVID-19 vaccines from provisional to full registration. This applies only to the formulations used for people aged ≥ 12 years.
It is the first COVID-19 vaccine to receive full registration within Australia.
Moderna’s original/ancestral strain COVID-19 vaccine formulation given to children aged 6 months to ≤ 5 years, and the Moderna SPIKEVAX bivalent vaccines remain provisionally registered only.
TGA: Moderna’s COVID-19 vaccine SPIKEVAX receives approval for full registration
For more information about the provision registration of COVID-19 vaccines in Australia, see our reference page.